Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Vaxcyte Inc

PCVX ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$58.07

▼ -1.34%

Market Cap $8.64B · Vol 242.73K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$8.64B

Mid Cap

Div Yield

N/A

EPS Growth

-48.65%

YoY

RSI (14)

57.44

Momentum

Beta

1.21

vs Market

52W High

$64.68

10.22% below

52W Low

$29.88

94.34% above

Volume

242.73K

Avg 371.28K

P/B

2.25

Price-to-book

ROE

-25.59%

Return on equity

Free Float

99.49%

Public shares

Shariah Compliance8 STANDARDS

✗ Vaxcyte Inc (PCVX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PCVX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+3.31%

+8.48%

+7.34%

YTD

+25.86%

+84.76%

+22.28%

+123.09%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-766,628,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-25.59%
ROA · ROIC	-23.54% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.25
P/FCF	N/A
EPS Growth	-48.65%
Outstanding Shares	148.81M

Technical Indicators

50-Day SMA	$54.67
200-Day SMA	$52.79
RSI (14)	57.44
Beta	1.21
52-Week High	$64.68
52-Week Low	$29.88

Volume Today	242.73K
Avg Daily Volume (30D)	371.28K
Relative Volume	0.65x
Volatility (10D)	32.03
Volatility (30D)	42.47
Free Float	99.49%

Analyst Consensus

BUY

Current Price $58.07

Mean Target $109.00

52W Low$29.88 52W High$64.68

Current

Target

$29.88 $64.68

Current Analyst target

+87.70% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG009PHHPP4

ISINUS92243G1085

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Vaxcyte, Inc. is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company's pipeline includes VAX-31, VAX-24 and VAX-XL. VAX-31, a 31-valent PCV candidate being evaluated in the OPUS Phase III adult clinical program and in a Phase II infant clinical program, is being developed for the prevention of IPD and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-XL leverages the Company’s carrier-sparing, site-specific conjugation technology. It is re-engineering the way highly complex vaccines are made through XpressCF, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.